Intervention
TIPS
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 7 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownLong-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and HypersplenismNCT07490405 · 2026-06-01
NOT_YET_RECRUITINGIncidence and Predictors of Post-TIPS Heart Failure in Patients With CirrhosisNCT05596253 · 2022-10-11
UNKNOWNManagement of Oxaliplatin-related Gastroesophageal Variceal BleedingNCT05141617 · 2021-11-03
UNKNOWNIncidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic PatientsNCT04387058 · 2019-06-16
UNKNOWNMagnetic Resonance Technics for the Assessment of Liver Function Before and After TIPSNCT03933891 · 2018-08-28
UNKNOWNViatorr CX Case-control Study for Complications of Portal HypertensionNCT03083925 · 2016-05-23
COMPLETEDPre-emptive Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Cystic Fibrosis Related Liver DiseaseNCT05037643 · 2007-06-01
COMPLETEDCommon conditions
Liver Cirrhosis3Transjugular Intrahepatic Portosystemic Shunt (TIPS)2Cirrhosis Portal1Cystic Fibrosis Liver Disease1Functional Magnetic Resonance Imaging1Gastroesophageal Varices Hemorrhage1Gastrointestinal Cancer1Heart Failure1Liver Cirrhoses1Portal Hypertension1Portal Hypertension Due to Cystic Fibrosis (Disorder)1Portal Hypertension, Noncirrhotic1Received Oxaliplatin-based Chemotherapy1
Leading sponsors
Trial status mix
UNKNOWN4
COMPLETED2
NOT_YET_RECRUITING1
Phase mix
NA3
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.